News | July 23, 2025
Lonza reports 19% growth in sales in H1
Upgrades 2025 full-year CDMO sales and margin outlook
Upgrades 2025 full-year CDMO sales and margin outlook
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
The new Zigly center features and offers comprehensive veterinary services
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
A triple-action Formula for comprehensive respiratory relief
Subscribe To Our Newsletter & Stay Updated
